abstract：:Primary effusion lymphoma (PEL) is a fatal malignancy, which typically presents as a lymphomatous effusion that later disseminates. Rapamycin (Rapa), which targets mTOR (mammalian target of Rapa), is currently evaluated as a treatment for PEL, but the recent development of PEL in Rapa-treated post-transplant recipient...

journal_title：Leukemia

authors： Gasperini P,Tosato G

更新日期：2009-10-01 00:00:00

abstract：:Nasal-type natural killer (NK) cell lymphoma is an infrequent aggressive malignant disease with very poor prognosis. We aimed to explore the possible role of the transcription factor STAT3 in the pathophysiology of this malignancy, as it was involved in oncogenesis and chemoresistance. For this, we established and cha...

journal_title：Leukemia

authors： Coppo P,Gouilleux-Gruart V,Huang Y,Bouhlal H,Bouamar H,Bouchet S,Perrot C,Vieillard V,Dartigues P,Gaulard P,Agbalika F,Douay L,Lassoued K,Gorin NC

更新日期：2009-09-01 00:00:00

abstract：:Multidrug resistance (MDR), a significant impediment to the successful treatment of cancer clinically, has been attributed to the overexpression of P-glycoprotein (P-gp), a plasma membrane multidrug efflux transporter. P-gp maintains sublethal intracellular drug concentrations by virtue of its drug efflux capacity. Th...

journal_title：Leukemia

authors： Bebawy M,Combes V,Lee E,Jaiswal R,Gong J,Bonhoure A,Grau GE

更新日期：2009-09-01 00:00:00

abstract：:Inhibition of NOTCH1 signaling with gamma-secretase inhibitors (GSIs) has been proposed as a molecularly targeted therapy in T-cell acute lymphoblastic leukemia (T-ALL). However, GSIs seem to have limited antileukemic activity in human T-ALL and are associated with severe gastrointestinal toxicity resulting from inhib...

journal_title：Leukemia

authors： Real PJ,Ferrando AA

更新日期：2009-08-01 00:00:00

abstract：:Runt-related transcription factor 1 (RUNX1) is essential for normal hematopoiesis. RUNX1 mutations have rarely been reported in chronic myelomonocytic leukemia (CMML). We examined RUNX1 mutations in 81 patients with CMML at initial diagnosis. Mutational analysis was performed on bone marrow samples by direct sequencin...

journal_title：Leukemia

authors： Kuo MC,Liang DC,Huang CF,Shih YS,Wu JH,Lin TL,Shih LY

更新日期：2009-08-01 00:00:00

abstract：:With the sequencing of the human genome and the development of new genomic technologies, biomedical discovery has been transformed. The applications of these new approaches are ever-expanding from disease classification, to identification of new targets, to outcome prediction. A logical next step is the integration of...

journal_title：Leukemia

authors： Stegmaier K

更新日期：2009-07-01 00:00:00

abstract：:Hemizygous deletions are common molecular abnormalities in cancer. In some cases, these deletions highlight chromosomal loci containing tumor suppressor genes that undergo homozygous inactivation. In other cases, hemizygous deletions cause disease by allelic insufficiency for one or more genes. As the intact allele ha...

journal_title：Leukemia

authors： Ebert BL

更新日期：2009-07-01 00:00:00

abstract：:The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues, azacitidine, decitabine and zebularine, which are currently studied as nonintensive therapy for myelodysplastic syndromes and acute myeloid leukemia (AML), differ in structure and metabolism, suggesting that they may have differential mol...

journal_title：Leukemia

authors： Flotho C,Claus R,Batz C,Schneider M,Sandrock I,Ihde S,Plass C,Niemeyer CM,Lübbert M

更新日期：2009-06-01 00:00:00

abstract：:We previously reported that susceptibility to childhood B cell precursor ALL (BCP ALL) is associated with HLA-DPB1 alleles having glutamic acid (E) rather than lysine (K) in the P4 antigenic peptide-binding pocket. Clustering approximately 90% of DPB1 alleles into DPB69E (DP2, 6, 8) and DPB69K (DP1, 3, 4) supertypes r...

journal_title：Leukemia

authors： Taylor GM,Hussain A,Verhage V,Thompson PD,Fergusson WD,Watkins G,Lightfoot T,Harrison CJ,Birch JM,UKCCS Investigators.

更新日期：2009-05-01 00:00:00

abstract：:We previously reported a strong IL4I1 gene expression in primary mediastinal B-cell lymphoma (PMBL) and recently identified the protein as a secreted L-phenylalanine oxidase, physiologically expressed by myeloid cells, which inhibits T-cell proliferation in vitro. Here, we analyzed the pattern of IL4I1 protein express...

journal_title：Leukemia

authors： Carbonnelle-Puscian A,Copie-Bergman C,Baia M,Martin-Garcia N,Allory Y,Haioun C,Crémades A,Abd-Alsamad I,Farcet JP,Gaulard P,Castellano F,Molinier-Frenkel V

更新日期：2009-05-01 00:00:00

abstract：:Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; ...

journal_title：Leukemia

authors： Poggi A,Catellani S,Garuti A,Pierri I,Gobbi M,Zocchi MR

更新日期：2009-04-01 00:00:00

abstract：:Human promonocytic cell line U937 cells can be induced to differentiate into macrophages by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA treatment induced the expression of the monocytic differentiation markers CD11b and CD36, with concomitant morphological changes. Moreover, TPA enhanced reactive ox...

journal_title：Leukemia

authors： Yamamoto T,Sakaguchi N,Hachiya M,Nakayama F,Yamakawa M,Akashi M

更新日期：2009-04-01 00:00:00

abstract：:Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell ly...

journal_title：Leukemia

authors： Boerma EG,Siebert R,Kluin PM,Baudis M

更新日期：2009-02-01 00:00:00

abstract：:To evaluate current detection methods for FIP1L1-PDGFRA in hypereosinophilic syndrome (HES), we developed a means to rapidly amplify genomic break points. We screened 202 cases and detected genomic junctions in all samples previously identified as RT-PCR positive (n=43). Genomic fusions were amplified by single step P...

journal_title：Leukemia

authors： Score J,Walz C,Jovanovic JV,Jones AV,Waghorn K,Hidalgo-Curtis C,Lin F,Grimwade D,Grand F,Reiter A,Cross NC

更新日期：2009-02-01 00:00:00

abstract：:Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-neg...

journal_title：Leukemia

authors： Chase A,Schultheis B,Kreil S,Baxter J,Hidalgo-Curtis C,Jones A,Zhang L,Grand FH,Melo JV,Cross NC

更新日期：2009-02-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by chronic proliferation of hematopoietic progenitors. We studied the telomere length (TL) of 335 MPN patients and 93 gender- and age-matched controls using a quantitative PCR method (relative TL calculated as the ratio of the amount of t...

journal_title：Leukemia

authors： Bernard L,Belisle C,Mollica L,Provost S,Roy DC,Gilliland DG,Levine RL,Busque L

更新日期：2009-02-01 00:00:00

abstract：:Malignant diseases induce immune responses against them which have variable success in controlling progression of disease. A variety of congenital and acquired disorders provide evidence in support of T cell or NK cell immune surveillance mechanisms in human hematological malignancies. Furthermore, clinical experience...

journal_title：Leukemia

authors： Barrett AJ,Savani BN

更新日期：2009-01-01 00:00:00

abstract：:The NUP214-ABL1 fusion kinase has recently been identified in 6% of patients with T-cell acute lymphoblastic leukemia. In contrast to the more common oncogenic ABL1 fusion BCR-ABL1, NUP214-ABL1 localizes to the nuclear pore complexes and has attenuated transforming properties in hematopoietic cells and in mouse bone m...

journal_title：Leukemia

authors： De Keersmaecker K,Versele M,Cools J,Superti-Furga G,Hantschel O

更新日期：2008-12-01 00:00:00

abstract：:On activation, umbilical cord blood (UCB) CD4(+) T cells demonstrate reduced expression of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), whereas maintaining equivalent interleukin-2 (IL-2) levels, as compared with adult peripheral blood (PB) CD4(+) T cells. Nuclear factor of activated T cel...

journal_title：Leukemia

authors： Lesniewski ML,Haviernik P,Weitzel RP,Kadereit S,Kozik MM,Fanning LR,Yang YC,Hegerfeldt Y,Finney MR,Ratajczak MZ,Greco N,Paul P,Maciejewski J,Laughlin MJ

更新日期：2008-12-01 00:00:00

abstract：:Inorganic arsenic trioxide (As(2)O(3)) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies...

journal_title：Leukemia

authors： Diaz Z,Mann KK,Marcoux S,Kourelis M,Colombo M,Komarnitsky PB,Miller WH Jr

更新日期：2008-10-01 00:00:00

abstract：:Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated t...

journal_title：Leukemia

authors： Breitkreutz I,Raab MS,Vallet S,Hideshima T,Raje N,Mitsiades C,Chauhan D,Okawa Y,Munshi NC,Richardson PG,Anderson KC

更新日期：2008-10-01 00:00:00

abstract：:Insertional activation of cellular proto-oncogenes by replication-defective retroviral vectors can trigger clonal dominance and leukemogenesis in animal models and clinical trials. Here, we addressed the leukemogenic potential of vectors expressing interleukin-2 receptor common gamma-chain (IL2RG), the coding sequence...

journal_title：Leukemia

authors： Modlich U,Schambach A,Brugman MH,Wicke DC,Knoess S,Li Z,Maetzig T,Rudolph C,Schlegelberger B,Baum C

更新日期：2008-08-01 00:00:00

abstract：:Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

journal_title：Leukemia

authors： Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

更新日期：2008-07-01 00:00:00

abstract：:The presence of rare malignant stem cells supplying a hierarchy of malignant cells has recently been reported. In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction. To understand the origin of malignant cells in primary human B-pre...

journal_title：Leukemia

authors： Kong Y,Yoshida S,Saito Y,Doi T,Nagatoshi Y,Fukata M,Saito N,Yang SM,Iwamoto C,Okamura J,Liu KY,Huang XJ,Lu DP,Shultz LD,Harada M,Ishikawa F

更新日期：2008-06-01 00:00:00

abstract：:Until 1990, the survival of children with acute lymphoblastic leukaemia (ALL) in Russia was below 10%. To establish a protocol feasible under conditions there, ALL-MB 91 was designed to avoid prolonged bone marrow aplasia, thereby reducing needs for extensive supportive care, blood transfusions, long-lasting hospitali...

journal_title：Leukemia

authors： Karachunskiy A,Herold R,von Stackelberg A,Miakova N,Timakow A,Mahortih T,Bajdun L,Maschan A,Fechina L,Shamardina A,Dudkin S,Lebedev V,Varfolomeeva S,Timofeeva V,Roumiantseva J,Chipsanova N,Rumjanzew A,Henze G

更新日期：2008-06-01 00:00:00

abstract：:Sorafenib, a novel drug for metastatic renal cancer, has broad-spectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and platelet-derived growth factor receptor. However, little is known about its effects on the immune system. In this report, we examine the e...

journal_title：Leukemia

authors： Zhao W,Gu YH,Song R,Qu BQ,Xu Q

更新日期：2008-06-01 00:00:00

abstract：:We have recently identified a human homolog of a fungal nuclear migration protein (hNUDC) that binds specifically with the extracellular domain of thrombopoietin receptor (Mpl). Preliminary studies with human CD34(+) cells cultured in serum-free medium and normal mice showed that hNUDC appears to act as a cytokine, tr...

journal_title：Leukemia

authors： Tang YS,Zhang YP,Xu P

更新日期：2008-05-01 00:00:00

abstract：:Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II st...

journal_title：Leukemia

authors： Quintás-Cardama A,Tong W,Kantarjian H,Thomas D,Ravandi F,Kornblau S,Manshouri T,Cortes JE,Garcia-Manero G,Verstovsek S

更新日期：2008-05-01 00:00:00

abstract：:Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

journal_title：Leukemia

authors： San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

更新日期：2008-04-01 00:00:00

abstract：:Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL). The 10-year update on the I-BFM-SG MRD study 91 demonstrates stable results (event-free survival), that is, standard ri...

journal_title：Leukemia

authors： Flohr T,Schrauder A,Cazzaniga G,Panzer-Grümayer R,van der Velden V,Fischer S,Stanulla M,Basso G,Niggli FK,Schäfer BW,Sutton R,Koehler R,Zimmermann M,Valsecchi MG,Gadner H,Masera G,Schrappe M,van Dongen JJ,Biondi A,B

更新日期：2008-04-01 00:00:00

abstract：:In patients with hematologic malignancy, invasive aspergillosis continues to be associated with high mortality even when treated with conventional antifungal therapy. To investigate novel antifungal agents, we compared 53 patients who received posaconazole salvage therapy to 52 contemporary control patients who receiv...

journal_title：Leukemia

authors： Raad II,Hanna HA,Boktour M,Jiang Y,Torres HA,Afif C,Kontoyiannis DP,Hachem RY

更新日期：2008-03-01 00:00:00

abstract：:In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range...

journal_title：Leukemia

authors： Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

更新日期：2008-03-01 00:00:00

abstract：:Conditionally replicating adenoviruses (CRAds) represent a promising new platform for anticancer therapy. However, CRAds have been evaluated little in hematopoietic malignancies because of the lack of expression of coxsackie adenovirus receptor (CAR) on their cell surface. In this study, we showed that CAR was express...

journal_title：Leukemia

authors： Qian W,Liu J,Tong Y,Yan S,Yang C,Yang M,Liu X

更新日期：2008-02-01 00:00:00

abstract：:We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

journal_title：Leukemia

authors： de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

更新日期：2008-02-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) consists of at least two major prognostic subgroups, characterized by different cellular and molecular markers. This observation sparked studies on the function and clinical importance of these markers. In order to address their function adequately, an efficient and reliable method f...

journal_title：Leukemia

authors： Van Bockstaele F,Pede V,Naessens E,Van Coppernolle S,Van Tendeloo V,Verhasselt B,Philippé J

更新日期：2008-02-01 00:00:00

abstract：:The optimal donor for a patient undergoing reduced-intensity stem cell transplantation remains a human leukocyte antigen (HLA)-matched relative. Alternative donors such as matched unrelated donors (MUDs), mismatched related donors (haploidentical), or unrelated umbilical cord blood (UCB) units have emerged as options ...

journal_title：Leukemia

authors： Chen YB,Spitzer TR

更新日期：2008-01-01 00:00:00

abstract：:Early in mammalian development, the stem cell leukemia (SCL/TAL1) gene and its distinct 3' enhancer (SCL 3'En) specify bipotential progenitor cells that give rise to blood and endothelium, thus termed hemangioblasts. We have previously detected a minor population of SCL (+) cells in the postnatal kidney. Here, we demo...

journal_title：Leukemia

authors： Dekel B,Metsuyanim S,Garcia AM,Quintero C,Sanchez MJ,Izraeli S

更新日期：2008-01-01 00:00:00

abstract：:The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)-chronic myelogenous leukemia, polycythemia vera (PV), essential thro...

journal_title：Leukemia

authors： Tefferi A,Vardiman JW

更新日期：2008-01-01 00:00:00

abstract：:Mesenchymal stem cells (MSC) possess anti-inflammatory properties and participate in tissue repair. We used MSC to heal therapy-induced tissue toxicity. Ten consecutive patients, treated with MSC due to tissue toxicity following allogeneic hematopoietic stem cell transplantation, (ASCT) were included. Their median age...

journal_title：Leukemia

authors： Ringdén O,Uzunel M,Sundberg B,Lönnies L,Nava S,Gustafsson J,Henningsohn L,Le Blanc K

更新日期：2007-11-01 00:00:00

abstract：:Natural killer (NK) cells are the first lymphocytes to recover after allogeneic stem cell transplantation (SCT) and can exert powerful graft-versus-leukemia (GVL) effects determining transplant outcome. Conditions governing NK cell alloreactivity and the role of NK recovery in sibling SCT are not well defined. NK cell...

journal_title：Leukemia

authors： Savani BN,Mielke S,Adams S,Uribe M,Rezvani K,Yong AS,Zeilah J,Kurlander R,Srinivasan R,Childs R,Hensel N,Barrett AJ

更新日期：2007-10-01 00:00:00